Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04401605 · ClinicalTrials.gov registry record · NA
Fermented Food-Supplemented Diet in Ulcerative Colitis
A NA study of Ulcerative Colitis and Inflammatory Bowel Diseases, sponsored by Stanford University.
- Recruiting
- Registry status
- NA
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT04401605: Recruiting NA study of Ulcerative Colitis and Inflammatory Bowel Diseases, sponsored by Stanford University.
NCT04401605 is a NA study of Ulcerative Colitis and Inflammatory Bowel Diseases that is actively recruiting participants, run by Stanford University. The registered enrollment target is 21 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04401605, a NA study of Ulcerative Colitis and Inflammatory Bowel Diseases, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see how a diet that supplements fermented foods effects inflammation and quality of life in patients with mild to moderate Ulcerative Colitis (UC). There is a paucity of research and an enormous need for better understanding of diet and intestinal inflammation. Fermented food have been shown to positively influence inflammatory cytokines and intestinal microbial diversity in healthy volunteers.
Primary Outcome
Change in fecal calprotectin
Conditions Studied
Interventions
- OTHER Fermented Food-supplemented Diet
- OTHER Regular Diet
Study Locations (1)
California
- Stanford University - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2020-09-14 |
| Est. Completion | 2027-06 |
| Phase | NA |
What NCT04401605 shows while recruiting
NCT04401605 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Ulcerative Colitis appearing as the primary indexed condition, and to 2 interventions - of which Fermented Food-supplemented Diet is the first listed.
NCT04401605 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04401605 about?
NCT04401605 is a clinical study titled "Fermented Food-Supplemented Diet in Ulcerative Colitis". The purpose of this study is to see how a diet that supplements fermented foods effects inflammation and quality of life in patients with mild to moderate Ulcerative Colitis (UC). There is a paucity of research and an enormous need for better understanding of diet and intestinal inflammation. Fermen...
What is the current status of trial NCT04401605?
This trial is currently recruiting. It is a NA study. The enrollment target is 21 participants. The study started on 2020-09-14. Estimated completion is 2027-06.
What conditions does trial NCT04401605 study?
This clinical trial studies the following conditions: Ulcerative Colitis, Inflammatory Bowel Diseases, Diet Modification.
What interventions are being tested in trial NCT04401605?
The interventions under investigation include: Fermented Food-supplemented Diet (OTHER), Regular Diet (OTHER).
Who is sponsoring clinical trial NCT04401605?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04401605 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04401605's enrollment target sits among peer trials
21 111th of 122 higher than 12 of 122 other Ulcerative Colitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
RECRUITING · NA
-
A Study of Endoscopic Sleeve Gastroplasty for Obesity in Ulcerative Colitis
RECRUITING · NA
-
Nicotinamide Riboside in Ulcerative Colitis
RECRUITING · NA
-
Impact of Prebiotics in Ulcerative Colitis
RECRUITING · NA
-
Tailored Anti-Inflammatory (A-I) Diet for Americans With Ulcerative Colitis (UC)
RECRUITING · NA
-
BOOM-IBD2 Pivotal Clinical Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI